

Future Leaders in the Biotech Industry

Featuring Rising Late-Stage Private Plays and Momentum-Building Public Companies

Thursday, April 8, 2010

New York City

Millennium Broadway

Hotel & Conference Center

In anticipation of a broadening market for biotech in 2010, Wall Street will be eager to meet with late-stage private companies and public companies poised to jump to the next tier of valuations. The 17th Annual *Future Leaders in the Biotech Industry* conference will be one of the Street's best venues to find these select opportunities.

The longest-running independent Wall Street conference serving the biotech community, *Future Leaders* connects leading portfolio managers, bankers and analysts with investor-validated, milestone-rich private and public companies in key therapeutic areas, offering new investment opportunities and the chance to find stories with tier-jumping potential. In its first 16 years, *Future Leaders* has showcased more than 450 of these stories.

This one-day, turf-neutral meeting ensures the best access to C-level biotech executives and decision makers in the investment community, allowing your company to present to an audience of industry leaders assembled by BioCentury and Thomson Reuters.

BioCentury™



THOMSON REUTERS

Future Leaders in the Biotech Industry

Presenting Companies

Presenting Companies are hand-picked by BioCentury based on rigorous selection criteria, including investor validation and upcoming milestones, informed by the collective intelligence of Thomson Reuters and the *Future Leaders* Sponsors.

Each Presenting Company provides a thorough 25-minute overview to fund managers who have been identified by Thomson Reuters as active biotech investors. At the 2009 *Future Leaders* conference, this hand-selected audience controlled more than \$130 billion in healthcare investments, with more than \$42 billion dedicated to biotech.

In addition, the turf-neutral setting provides unique access to a cross-section of sellside analysts and investment bankers in a single location, as well as representatives from pharmaceutical and top-tier biotech companies.

Private conference rooms and special events allow Sponsors, Presenting Companies and audience members to network and conduct one-on-one business meetings throughout the day.

"We have found *Future Leaders* an exceptional venue for meeting with a wide audience of premier investors. It is also an excellent opportunity for networking with other small company CEOs and the investment banking community and thus an excellent opportunity for keeping on the cutting edge of new trends in the industry. It is a must do conference."

Arlene Morris, CEO, Affymax

Benefits for Presenting Companies


- Conference marketing focused on highly qualified financial professionals, including buy-side, sell-side and banking institutions
- Targeted marketing to key business development professionals in pharma and big biotech
- High-level sponsors validate conference value
- Full 25-minute presentation to investors followed by one-hour breakout session
- Opportunity to webcast presentation to reach additional audiences
- Private meeting space available without additional charge
- Designated Presenting Company table at Networking Luncheon
- Networking Reception at close of conference
- Full company profile from *BCIQ: BioCentury Online Intelligence™* available to all registrants
- Company logo posted on official 2010 *Future Leaders* website for one year after event

For the 2009 list of Presenting Companies that have participated in *Future Leaders*, please go to the *Future Leaders* website at www.biocentury.com.

"*Future Leaders* had a great audience and the mix was exceptionally good: A lot of investors and a range of sell-side analysts, clinical experts and pharmaceutical business development representatives. We had the most intense breakout session we've ever had."

**Dr. Christian Itin,
President & CEO, Micromet**

2009 Attendees Represented a Broad Cross Section of The Industry



Future Leaders in the Biotech Industry

Sponsors

Future Leaders pioneered the “turf-neutral” concept on Wall Street, creating an open door for all members of the financial community to do business with independently selected Presenting Companies.

This approach has been possible because of the durable support of the Gold and Contributing Sponsors, whose endorsement enables BioCentury and Thomson Reuters to make this truly “A Collaborative Gathering of the Corporate and Investment Communities.”

Benefits for Sponsors

- Nominate Presenting Companies
- Exclusive access to the presenting company executives: last year's meeting included more than 66 C-level executives, including 39 CEOs and/or presidents and 19 CFOs.
- Sponsor recognition in targeted promotions to BioCentury's and Thomson Reuters' proprietary databases, including:
 - Announcements in *BioCentury: The Bernstein Report on BioBusiness*® and *BioCentury Extra*, BioCentury's daily executive news service
 - Promotional e-mails to an international industry audience
- Access to the pre-registration list in advance of the meeting
- Access to onsite meeting space
- Recognition of your firm on the Conference Book cover
- Your firm's logo posted on the 2009 *Future Leaders* website for one year after event
- Recognition in welcoming remarks
- Opportunity to introduce Presenting Companies to the audience on day of conference
- Distribute your company's collateral at venue

2009 Gold Sponsor

Cooley
GODWARD KRONISH LLP

2009 Contributing Sponsors

Apposite Capital LLP

Domain Associates

EMD Serono

GE Healthcare Financial Services -
Life Science Finance

Ladenburg Thalmann

OrbiMed Healthcare Fund Management

Rodman & Renshaw

WBB Securities, LLC

Wedbush Pacific Growth Life Sciences

"*Future Leaders* provides Cooley with unmatched visibility among top decision makers on Wall Street and in the biopharma industry. What's more, this conference delivers tremendous value to the institutional investment community by clearly identifying those companies that are poised to lead the industry into a new era."

Laura Berezin, Partner, Cooley Godward Kronish

"Over the years we have enjoyed the visibility the *Future Leaders* conference brings to Domain's portfolio companies. The turf-neutral nature of the meeting is a wonderful venue for our companies to meet many interested parties involved in key aspects of the industry."

Nicole Vitullo, Partner, Domain Associates

About BioCentury

BioCentury Publications, Inc. provides essential industry intelligence across the full spectrum of the industry's value chain from research through commercialization, reaching a global audience of biotech and pharmaceutical executives and investors. With 15 years of service, the company is privately owned and does not invest in or recommend individual stock purchases; therefore, subscribers benefit from BioCentury's independent perspective and trustworthy content, built on deep knowledge and data-driven analysis. For more information, please visit www.biocentury.com.

BioCentury™

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and NASDAQ (NASDAQ: TRIN). For more information, go to www.thomsonreuters.com.



THOMSON REUTERS